News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellumen, Inc. Expands Discovery Toxicology Services with Cardiac Hypertrophy Panel


12/17/2008 11:36:02 AM

PITTSBURGH--(BUSINESS WIRE)--Cellumen, a discovery toxicology company, today announced a new Cellular Systems Biology (CSB) panel to predict cardiac hypertrophy earlier in the drug discovery and development process. By integrating this new panel into Cellumen’s CellCiphr Discovery Toxicology profiling services, drug companies can now save millions of dollars in development costs that are typically wasted by not identifying toxic compounds earlier.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES